Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–87.

Article  PubMed  Google Scholar 

Jacob SL, Huppert LA, Rugo HS. Role of immunotherapy in breast cancer. JCO Oncol Pract. 2023. https://doi.org/10.1200/op.22.00483.

Article  PubMed  Google Scholar 

Miglietta F, Griguolo G, Guarneri V, Dieci MV. Programmed cell death ligand 1 in breast cancer: technical aspects, prognostic implications, and predictive value. Oncologist. 2019;24(11):e1055–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen N, Higashiyama N, Hoyos V. Predictive biomarkers of immune checkpoint inhibitor response in breast cancer: looking beyond tumoral PD-L1. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9121863

Article  PubMed  PubMed Central  Google Scholar 

Isaacs J, Anders C, McArthur H, Force J. Biomarkers of immune checkpoint blockade response in triple-negative breast cancer. Curr Treat Options Oncol. 2021;22(5):38.

Article  PubMed  Google Scholar 

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.

Article  CAS  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28.

Article  PubMed  Google Scholar 

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021. https://doi.org/10.1016/S1470-2045(20)30754-3.

Article  PubMed  Google Scholar 

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100.

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21.

Article  CAS  PubMed  Google Scholar 

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004.

Article  CAS  PubMed  Google Scholar 

Emens LA. Immunotherapy in triple-negative breast cancer. Cancer J. 2021;27(1):59–66.

Article  CAS  PubMed  Google Scholar 

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534–43.

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67.

Article  CAS  PubMed  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–26.

Article  CAS  PubMed  Google Scholar 

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–93.

Article  CAS  PubMed  Google Scholar 

Korde LA, Somerfield MR, Hershman DL. Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40(15):1696–8.

Article  PubMed  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.

Article  CAS  PubMed  Google Scholar 

Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–17.

Article  CAS  PubMed  Google Scholar 

Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the impassion130 study. J Natl Cancer Inst. 2021;113(8):1005–16.

Article  PubMed  PubMed Central  Google Scholar 

Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, et al. Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer. Clin Cancer Res. 2021;27(20):5628–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emens LA, Loi S. Immunotherapy approaches for breast cancer patients in 2023. Cold Spring Harb Perspect Med. 2023. https://doi.org/10.1101/cshperspect.a041332

Article  PubMed  Google Scholar 

Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J Natl Cancer Inst. 2021;113(12):1733–43.

Article  PubMed  PubMed Central  Google Scholar 

Ahn S, Woo JW, Kim H, Cho EY, Kim A, Kim JY, et al. Programmed death ligand 1 immunohistochemistry in triple-negative breast cancer: evaluation of inter-pathologist concordance and inter-assay variability. J Breast Cancer. 2021;24(3):266–79.

Article  PubMed  PubMed Central  Google Scholar 

Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, et al. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol. 2021;108:42–50.

Article  CAS  PubMed  Google Scholar 

Lee SE, Park HY, Lim SD, Han HS, Yoo YB, Kim WS. Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer. J Breast Cancer. 2020;23(3):303–13.

Article  PubMed  PubMed Central  Google Scholar 

Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, et al. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast. 2021;60:238–44.

Article  PubMed  PubMed Central  Google Scholar 

Pang JB, Castles B, Byrne DJ, Button P, Hendry S, Lakhani SR, et al. SP142 PD-L1 scoring shows high interobserver and intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3. Am J Surg Pathol. 2021;45(8):1108–17.

Article  PubMed  PubMed Central  Google Scholar 

Schmidt G, Guhl MM, Solomayer EF, Wagenpfeil G, Hammadeh ME, Juhasz-Boess I, et al. Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients. Arch Gynecol Obstet. 2022. https://doi.org/10.1007/s00404-022-06529-w.

Article  PubMed  PubMed Central  Google Scholar 

Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, et al. The sweden cancerome analysis network - breast (SCAN-B) initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.

Article  PubMed  PubMed Central  Google Scholar 

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working group 2014. Ann Oncol. 2015;26(2):259–71.

Article  CAS  PubMed  Google Scholar 

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–69.

Article  PubMed  PubMed Central  Google Scholar 

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127–32.

Article  PubMed